drugset / Trial / NCT06866574
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
Phase 3
Active not recruiting
9300 enrolled
Xiamen University
Xiamen Innovax Biotech Co., Ltd · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
This phase III clinical trial was designed to evaluate the efficacy, immunogenicity and safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) manufactured by Xiamen Innovax Biotech CO., LTD., in Chinese males aged 18-45 years.
Timeline
- Start
- 2025-04-11
- Primary completion
- 2031-09-30
- Completion
- 2031-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.coli) | Vaccine | 0.5 ml | Intramuscular |